Literature DB >> 28499079

Development of an atrophic acne scar risk assessment tool.

J Tan1, D Thiboutot2, H Gollnick3, S Kang4, A Layton5, J J Leyden6, V Torres7, J Guillemot8,9, B Dréno10.   

Abstract

BACKGROUND: Acne is a chronic dermatological disease predominantly afflicting young adults and is often associated with the development of scars. Acne scarring is usually avoidable when acne is managed early and effectively. However, acne patients often fail to seek early treatment. New and innovative tools to raise awareness are needed.
OBJECTIVE: This study presents the development and assessment of a tool aiming to assess the risk of atrophic acne scars.
METHODS: A systematic literature review of clinical risk factors for acne scars, a Delphi-like survey of dermatological experts in acne and secondary data analysis, were conducted to produce an evidence-based risk assessment tool. The tool was assessed both with a sample of young adults with and without scars and was assessed via a database cross-validation.
RESULTS: A self-administered tool for risk assessment of developing atrophic acne scars in young adults was developed. It is a readily comprehensible and practical tool for population education and for use in medical practices. It comprises of four risk factors: worst ever severity of acne, duration of acne, family history of atrophic acne scars and lesion manipulation behaviours. It provides a dichotomous outcome: lower vs. higher risk of developing scars, thereby categorizing nearly two-thirds of the population correctly, with sensitivity of 82% and specificity of 43%.
CONCLUSION: The present tool was developed as a response to current challenges in acne scar prevention. A potential benefit is to encourage those at risk to self-identify and to seek active intervention of their acne. In clinical practice, we expect this tool may help clinicians identify patients at risk of atrophic acne scarring and underscore their requirement for rapid and effective acne treatment.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2017        PMID: 28499079     DOI: 10.1111/jdv.14325

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  5 in total

1.  Evaluation of psychological well-being and social impact of atrophic acne scarring: A multinational, mixed-methods study.

Authors:  Jerry Tan; Stefan Beissert; Fran Cook-Bolden; Rajeev Chavda; Julie Harper; Adelaide Hebert; Edward Lain; Alison Layton; Marco Rocha; Jonathan Weiss; Brigitte Dréno
Journal:  JAAD Int       Date:  2021-12-23

2.  Double-blind, randomized controlled trial comparing the use of microneedling alone versus chemical peeling alone versus a combination of microneedling and chemical peeling in the treatment of atrophic post-acne scars. An assessment of clinical effectiveness and patients' quality-of-life.

Authors:  Agata Pakla-Misiur; Marcelina Grochowiec; Aleksandra Lesiak; Igor A Bednarski
Journal:  Postepy Dermatol Alergol       Date:  2021-09-17       Impact factor: 1.837

3.  Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panel.

Authors:  Alison Layton; Andrew Alexis; Hilary Baldwin; Stefan Beissert; Vincenzo Bettoli; James Del Rosso; Brigitte Dréno; Linda Stein Gold; Julie Harper; Charles Lynde; Diane Thiboutot; Jonathan Weiss; Jerry Tan
Journal:  JAAD Int       Date:  2021-08-17

4.  Combined Effect of Microneedling and Platelet-Rich Plasma for the Treatment of Acne Scars: A Meta-Analysis.

Authors:  Cheng Kang; Dakai Lu
Journal:  Front Med (Lausanne)       Date:  2022-02-14

5.  Pilot study for the evaluation and adaptation of a Four Item-Acne-Scar Risk Assessment Tool (4-ASRAT): a resource to estimate the risk of acne-induced scars.

Authors:  Jorge Estrella Porter; Mikaela Camacho; María Isabel Viteri; Katherine Aguilar; Drifa Belhadi; Vincenzo Bettoli; Anita Del Rocío Buestán; Brigitte Dréno; Pablo Endara; Alison Layton; Nelly Machado; Rosa Mateus; Jerry Tan; Enrique Terán; Paola Yépez; Jonathan Guillemot
Journal:  F1000Res       Date:  2020-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.